The emergence of microbes resistant to common antibiotics represent a current treat to human health. It has been recently recognized that non-antibiotic labeled drugs may promote antibiotic-resistance mechanisms in the human microbiome by presenting a secondary antibiotic activity; hence, the development of computer-assisted procedures to identify antibiotic activity in human-targeted compounds may assist in preventing the emergence of resistant microbes. In this regard, it is worth noting that while most antibiotics used to treat human infectious diseases are non-peptidic compounds, most known antimicrobials nowadays are peptides, therefore all computer-based models aimed to predict antimicrobials either use small datasets of non-peptidic compounds rendering predictions with poor reliability or they predict antimicrobial peptides that are not currently used in humans. Here we report a machine-learning-based approach trained to identify gut antimicrobial compounds; a unique aspect of our model is the use of heterologous training sets, in which peptide and non-peptide antimicrobial compounds were used to increase the size of the training data set. Our results show that combining peptide and non-peptide antimicrobial compounds rendered the best classification of gut antimicrobial compounds. Furthermore, this classification model was tested on the latest human-approved drugs expecting to identify antibiotics with broad-spectrum activity and our results show that the model rendered predictions consistent with current knowledge about broad-spectrum antibiotics. Therefore, heterologous machine learning rendered an efficient computational approach to classify antimicrobial compounds.

Selfie-based biometrics has great potential for a wide range of applications since, e.g. periocular verification is contactless and is safe to use in pandemics such as COVID-19, when a major portion of a face is covered by a facial mask. Despite its advantages, selfie-based biometrics presents challenges since there is limited control over data acquisition at different distances. Therefore, Super-Resolution (SR) has to be used to increase the quality of the eye images and to keep or improve the recognition performance. We propose an Efficient Single Image Super-Resolution algorithm, which takes into account a trade-off between the efficiency and the size of its filters. To that end, the method implements a loss function based on the Sharpness metric used to evaluate iris images quality. Our method drastically reduces the number of parameters compared to the state-of-the-art: from 2,170,142 to 28,654. Our best results on remote verification systems with no redimensioning reached an EER of 8.89% for FaceNet, 12.14% for VGGFace, and 12.81% for ArcFace. Then, embedding vectors were extracted from SR images, the FaceNet-based system yielded an EER of 8.92% for a resizing of x2, 8.85% for x3, and 9.32% for x4.

Polypharmacologic human-targeted antimicrobials (polyHAM) are potentially useful in the treatment of complex human diseases where the microbiome is important (e.g., diabetes, hypertension). We previously reported a machine-learning approach to identify polyHAM from FDA-approved human targeted drugs using a heterologous approach (training with peptides and non-peptide compounds). Here we discover that polyHAM are more likely to be found among antimicrobials displaying a broad-spectrum antibiotic activity and that topological, but not chemical features, are most informative to classify this activity. A heterologous machine-learning approach was trained with broad-spectrum antimicrobials and tested with human metabolites; these metabolites were labeled as antimicrobials or non-antimicrobials based on a naïve text-mining approach. Human metabolites are not commonly recognized as antimicrobials yet circulate in the human body where microbes are found and our heterologous model was able to classify those with antimicrobial activity. These results provide the basis to develop applications aimed to design human diets that purposely alter metabolic compounds proportions as a way to control human microbiome.